Standardized Mite Mix, Dermatophagoides pteronyssinus and Dermatophagoides farinae, 10000 AU per mL 5000 [AU]/mL; 5000 [AU]/mL Injection, Solution, 30 mL — NDC 65044-6691-3 (Billing 65044-6691-03)
This is a package of 30 mL of Standardized Mite Mix, Dermatophagoides pteronyssinus and Dermatophagoides farinae, 10000 AU per mL 5000 [AU]/mL; 5000 [AU]/mL Injection, Solution from Jubilant HollisterStier LLC, first listed with the FDA May 1988 and currently FDA-listed.
NDC database record
One package, one record: these facts belong to NDC 65044-6691-3 alone.
- Record
- FDA NDC Directory package listing · Standardized allergenic
- Code segments
- 65044 labeler · 6691 product · 3 package
- Package marketed since
- May 26, 1988
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2027
- Barcode (UPC-A, from the NDC)
- 3 6504466913 3
- FDA record last changed
- Nov 19, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
- RxNorm (NLM RxNav) · catalog refreshed Nov 19, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Nov 19, 2026
Clinical
Patient education
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Nov 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Nov 19, 2026
- CMS Part D plan pricing files · refreshed Oct 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 65044-6691-02 65044-6691-2 Main listing | 10 mL in 1 VIAL | 1988-05-26 | — | Active |
| 65044-6691-03 You're viewing this | 30 mL in 1 VIAL | 1988-05-26 | — | Active |
| 65044-6691-04 65044-6691-4 | 50 mL in 1 VIAL | 1988-05-26 | — | Active |
You're viewing one of 3 pack sizes for this product.
Pack size FAQ
What quantity is in this package?
How does this package differ from NDC 65044-6691-02?
What NDC number is used to bill for this package of Standardized Mite Mix, Dermatophagoides pteronyssinus and Dermatophagoides farinae, 10000 AU per mL 5000 [AU]/mL; 5000 [AU]/mL Injection, Solution?
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Standardized Mite, Mixed 10000 [AU]/mL; 10000 [AU]/mL 00268-7002-10 | ALK-Abello, | 10 ml | — | — | FDA listed | — |
| Standardized Mite, Mixed 5000 [AU]/mL; 5000 [AU]/mL 00268-8116-06 | ALK-Abello, | 5.5 ml | — | — | FDA listed | — |
| Standardized Mite Mix Dermatophagoides farinae and Dermatophagoides pteronyssinus 5000 [AU]/mL; 5000 [AU]/mL 22840-0037-03 | Greer | 5 ml | — | — | FDA listed | — |
| Standardized Mite Mix, Dermatophagoides pteronyssinus and Dermatophagoides farinae, 10000 AU per mL 5000 [AU]/mL; 5000 [AU]/mLthis 65044-6691-03 | Jubilant | 30 ml | — | — | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA Purple Book · refreshed Nov 5, 2026
- CMS NADAC weekly file
Availability & biosimilar status
Biologics have no small-molecule generics; biosimilar competition is tracked in the FDA Purple Book.
Where does this data come from?
- FDA Purple Book · refreshed Nov 5, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII PDC6A3C0OX
Glycerin is a clear, thick liquid derived from plant oils or fats. It acts as a humectant to retain moisture, a sweetener, and a solvent in medications.
-
UNII 8MDF5V39QO
A white powder form of baking soda that acts as a buffer and pH regulator in medicines. It helps maintain the right acid-base balance and may aid tablet disintegration.
-
UNII 451W47IQ8X
Sodium chloride is common table salt. It's used in medicines as a buffer to maintain proper pH, as a filler to add bulk, or to adjust the osmotic balance in liquid formulations.
3 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Nov 21, 2026
- FDA openFDA NDC Directory · synced Nov 19, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Jubilant HollisterStier LLC labeler code 65044
- Insects whole body cockroach mix .1 g/mL; .1 g/mL Injection, Solution NDC 65044-6585-1
- Insects whole body cockroach mix .1 g/mL; .1 g/mL Injection, Solution NDC 65044-6587-2
- Insects whole body cockroach mix 20000 [PNU]/mL; 20000 [PNU]/mL Injection, Solution NDC 65044-6588-2
- Insects whole body cockroach mix 20000 [PNU]/mL; 20000 [PNU]/mL Injection, Solution NDC 65044-6589-2
- Insects whole body cockroach mix 5000 [PNU]/mL; 5000 [PNU]/mL Injection, Solution NDC 65044-6590-2
- Standardized Mite Mix, Dermatophagoides pteronyssinus and Dermatophagoides farinae, 30000 AU per mL 15000 [AU]/mL; 15000 [AU]/mL Injection, Solution NDC 65044-6690-2
- Standardized Mite, Dermatophagoides pteronyssinus, Scratch or Bulk, 30000 AU per mL 30000 [AU]/mL Injection, Solution NDC 65044-6692-1
- Standardized Mite, Dermatophagoides pteronyssinus, Bulk, 10000 AU per mL 10000 [AU]/mL Injection, Solution NDC 65044-6695-2
- Standardized Mite, Dermatophagoides farinae, Scratch or Bulk, 30000 AU per mL 30000 [AU]/mL Injection, Solution NDC 65044-6720-1
- Standardized Mite, Dermatophagoides farinae, Bulk, 10000 AU per mL 10000 [AU]/mL Injection, Solution NDC 65044-6723-2
- rilonacept 160 mg/2mL Injection, Powder, Lyophilized, For Solution NDC 65044-7168-1
- amphotericin b 50 mg/12.5mL Injection, Powder, Lyophilized, For Solution NDC 65044-7183-1
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- Drugs@FDA
Full FDA label FDA SPL
🚨 Boxed Warning ▾
This product is intended for use only by licensed medical personnel experienced in administering allergenic extracts and trained to provide immediate emergency treatment in the event of a life-threatening reaction. Allergenic extracts may potentially elicit a severe life-threatening systemic reaction, rarely resulting in death. 1 Therefore, emergency measures and personnel trained in their use should be available immediately in the event of such a reaction.
Patients should be instructed to recognize adverse reaction symptoms and cautioned to contact the physician's office if symptoms occur. Standardized glycerinated extracts may be more potent than regular extracts and therefore, are not directly interchangeable with non-standardized extracts, or other manufacturers' products. This product should never be injected intravenously.
Refer also to the WARNINGS , PRECAUTIONS , ADVERSE REACTIONS and OVERDOSE sections for further discussion.
WARNING: IF CHANGING TO A DIFFERENT LOT OF STANDARDIZED EXTRACT: Even though it is the same formula and concentration, the first dose of the new extract should not exceed 50% of the last administered dose from the previous extract. IF THE STANDARDIZED EXTRACT PREVIOUSLY USED WAS FROM ANOTHER MANUFACTURER: Since manufacturing processes and sources of raw materials differ among manufacturers, the interchangeability of extracts from different manufacturers cannot be insured. The starting dose of the standardized glycerinated extract therefore should be greatly decreased even though the extract is the same formula and dilution.
Initiate therapy as though patient had not been receiving immunotherapy, or determine initial dose by skin test using serial dilutions of the extract. In highly sensitive individuals, the skin test method may be preferable. See DOSAGE AND ADMINISTRATION and ADVERSE REACTIONS Sections.
IF A PROLONGED PERIOD OF TIME HAS ELAPSED SINCE THE LAST INJECTION: Patients may lose tolerance for allergen injections during prolonged periods between doses. The duration of tolerance is an individual characteristic and varies from patient to patient. In general, the longer the lapse in the injection schedule, the greater dose reduction required.
If the interval since last dose is over four weeks, perform skin tests to determine starting dose. IF THE PREVIOUS EXTRACT WAS OUTDATED: The dating period for allergenic extracts indicates the time that they can be expected to remain potent under refrigerated storage conditions (2° - 8° C). During the storage of extracts, even under ideal conditions, some loss of potency occurs.
For this reason, extracts should not be used beyond their expiration date. If a patient has been receiving injections of an outdated extract, he may experience excessive local or systemic reactions when changed to a new, and possibly more potent extract. In general, the longer the material has been outdated, the greater the dose reduction necessary for the fresh extract.
IF THE PREVIOUS EXTRACT WAS NON-STANDARDIZED: Standardized extracts may be more potent than non-standardized extracts. Initiate therapy as though the patient had not been receiving immunotherapy, or determine initial dose by skin test using serial dilutions of the extract. See PRECAUTIONS and DOSAGE AND ADMINISTRATION Sections.
IF ANY OTHER CHANGES HAVE BEEN MADE IN THE EXTRACT CONCENTRATE FORMULA: Changes other than those listed above may include situations such as a redistribution of component parts or percentages, a difference in extracting fluid (i.e., change from non-glycerin extracts to 50% glycerin extracts), combining two or more stock concentrates, or any other change. It should be recognized that any change in formula can affect a patient's tolerance of the treatment. The usual 1/2 of the previous dose for a new extract may produce an adverse reaction; extra dilutions are recommended whenever starting a revised formula.
The greater the change, the greater the number of dilutions required.
🎯 Indications and Usage ▾
INDICATIONS AND USAGE: 16, 17, 18, 26 Standardized glycerinated allergenic extracts are indicated for use in diagnosis and immunotherapy of patients presenting symptoms of allergy (hay fever, rhinitis, etc.) to specific environmental allergens. The selection of allergenic extracts to be used should be based on a thorough and carefully taken history of hypersensitivity, and confirmed by skin testing. 20, 21 The use of mixed or unrelated antigens for skin testing is not recommended since, in the case of a positive reaction, it does not indicate which component of the mix is responsible for the reaction, while, in the case of a negative reaction, it fails to indicate whether the individual antigens at full concentration would give a positive reaction.
Utilization of such mixes for compounding a treatment may result, in the former case, in administering unnecessary antigens and, in the latter case, in the omission of a needed allergen. Allergens to which a patient is extremely sensitive should not be included in treatment mixes with allergens to which there is much less sensitivity, but should be administered separately. This allows individualized and better control of dosage increases, including adjustments in dosage becoming necessary after severe reactions which may occur to the highly reactive allergen.
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION: 1. General Sterile aqueous diluent containing human serum albumin [Albumin Saline with Phenol (0.4%)] or diluent of 50% glycerin may be used when preparing dilutions of the concentrate for immunotherapy. For intradermal testing dilutions, Albumin Saline with Phenol is recommended.
Dilutions should be made accurately and aseptically, using sterile diluent, vials, syringes, etc. Mix thoroughly and gently by rocking or swirling. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
2. Diagnosis To identify highly sensitive individuals and as a safety precaution, it is recommended that a scratch, prick or puncture test using a drop of the extract concentrate be performed prior to initiating intradermal testing. Prick tests are performed by placing a drop of extract on the skin and piercing through the drop into the skin with a slight lifting motion.
Puncture testing is performed by placing a drop of extract concentrate on the skin and puncturing the skin through the drop with a small needle such as a Prick Lancetter. Fifteen minutes after puncture is made the diameter of wheal and erythema reactions are measured, and the sensitivity class of the patient determined by the table presented at end of Diagnosis Section. Less sensitive individuals (Class 0 to 1+) can be tested intradermally with the recommended dilutions of the extract concentrate (See intradermal testing instructions).
The skin test concentration of 30,000 AU/mL in dropper vials is used for scratch, prick or puncture testing. Puncture tests performed on 12 selected highly sensitive subjects showed the following: Species Mean ∑ Wheal ± Std/ Dev (mm) Mean ∑ Erythema ± Std. Dev (mm) D. farinae 22.4 ± 10.7 82.3 ±
21.7D. pteronyssinus 24.0 ± 9.9 89.3 ± 24.5 ∑ equals the sum of the longest diameter and the mid-point orthogonal diameter. Extract for intradermal testing should be prepared by diluting the 30,000 AU/mL stock concentrate, provided in multiple-dose vials, with sterile aqueous diluent (refer to the dilution table displayed in the immunotherapy section below). To administer the intradermal strength dilutions, a 1 mL tuberculin syringe with a short 27-gauge needle should be used.
The needle is inserted intradermally at a 30° angle, bevel down, and 0.02 to 0.05 mL of the extract is injected. Fifteen minutes following injection, the diameter of wheal and erythema reactions are measured, and the patient's sensitivity class is determined by the table on the following page. Intradermal skin test results in selected highly sensitive subjects are presented for reference purposes: Allergen Number of Persons Mean AU/mL that Elicited ∑E = 50mm 2 Std.
Dev Range D. farinae 12 0.0609 0.0015 - 2.6016 D. pteronyssinus 12 0.0333 0.0003 - 4.0077 Intradermal extract should be used as follows: a. Patients with a negative scratch, prick or puncture test: Patients who do not react to a valid scratch, prick or puncture test should be tested intradermally with 0.02 to 0.05 mL of a 30 AU/mL extract solution. If this test is negative, a second intradermal test may be performed using a 300 AU/mL extract solution.
The negative control used with this latter dilution should contain 0.5% glycerin. b. Patients tested only by the intradermal method: Patients suspected of being highly allergic should be tested with 0.02 to 0.05 mL of a solution containing
0.03AU/mL. A negative test should be followed by repeat tests using progressively stronger concentrations until the maximum recommended strength of 300 AU/mL is reached. The negative control used with this latter dilution should contain 0.5% glycerin.
Skin tests are graded in terms of the wheal and erythema response noted at 10 to 20 minutes. Wheal and erythema size may be recorded by actual measurement of the extent of both responses. Refer to the following table to determine the skin test sensitivity class.
The cor… [Excerpted — this section continues on DailyMed.]
⛔ Contraindications ▾
CONTRAINDICATIONS: There are no known absolute contraindications to immunotherapy. See PRECAUTIONS for pregnancy risks. Patients with cardiovascular diseases or pulmonary diseases such as symptomatic asthma, and/or those who are receiving cardiovascular drugs such as beta blockers, may be at higher risk for severe adverse reactions.
These patients may also be more refractory to the normal allergy treatment regimen. Patients should be treated only if the benefit of treatment outweighs the risks. 1 Any injections, including immunotherapy, should be avoided in patients with a bleeding tendency.
Since there are differences of opinion concerning the possibility of routine immunizations exacerbating autoimmune diseases, immunotherapy should be given cautiously to patients with autoimmune diseases, and only if the risk from exposure to the allergen is greater than the risk of exacerbating the autoimmune process.
⚠️ Warnings ▾
WARNINGS: See WARNINGS at the beginning of this instruction sheet. Allergenic extract should be temporarily withheld from patients or the dose adjusted downward if any of the following conditions exist: (1) severe symptoms of rhinitis and/or asthma; (2) infection or flu accompanied by fever, or (3) exposure to excessive amounts of clinically relevant allergen prior to a scheduled injection. Do not start immunotherapy during a period of symptoms due to exposure.
Since the individual components of the extract are those to which the patient is allergic, and to which he or she will be exposed, typical allergic symptoms may follow shortly after the injection, particularly when the antigen load from exposure plus the injected antigen exceeds the patient's antigen tolerance. THE CONCENTRATE SHOULD NOT BE INJECTED AT ANY TIME UNLESS TOLERANCE HAS BEEN ESTABLISHED. DILUTE CONCENTRATED EXTRACTS WITH STERILE ALBUMIN SALINE WITH PHENOL (0.4%) FOR INTRADERMAL TESTING.
INJECTIONS SHOULD NEVER BE GIVEN INTRAVENOUSLY. Subcutaneous injection is recommended. Intracutaneous or intramuscular injections may produce large local reactions or be excessively painful.
AFTER INSERTING NEEDLE SUBCUTANEOUSLY, BUT BEFORE INJECTING, ALWAYS WITHDRAW THE PLUNGER SLIGHTLY. IF BLOOD APPEARS IN THE SYRINGE, CHANGE NEEDLE AND GIVE THE INJECTION IN ANOTHER SITE.
Proper selection of the dose and careful injection should prevent most systemic reactions. It must be remembered, however, that allergenic extracts are highly potent in sensitive individuals, and that systemic reactions of varying degrees of severity may occur, including urticaria, rhinitis, conjunctivitis, wheezing, coughing, angioedema, hypotension, bradycardia, pallor, laryngeal edema, fainting, or even anaphylactic shock and death. Patients should be informed of this, and the precautions should be discussed prior to immunotherapy.
(See PRECAUTIONS below.) Severe systemic reactions should be treated as indicated in the ADVERSE REACTIONS Section.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS: 1. Local Reactions Some erythema, swelling or pruritus at the site of injection are common, the extent varying with the patient. Such reactions should not be considered significant unless they persist for at least 24 hours.
Local reactions (erythema or swelling) which exceed 4-5 cm in diameter are not only uncomfortable, but also indicate the possibility of a systemic reaction if dosage is increased. In such cases the dosage should be reduced to the last level not causing the reaction and maintained at this level for two or three treatments before cautiously increasing again. Large persistent local reactions may be treated by local cold, wet dressings and/or the use of oral antihistamines.
They should be considered a warning of possible severe systemic reactions and an indication of the need for temporarily reduced dosages. A mild burning immediately after the injection is to be expected. This usually leaves in 10 to 20 seconds.
2. Systemic Reactions With careful attention to dosage and administration, systemic reactions occur infrequently, but it cannot be overemphasized that in sensitive individuals, any injection could result in anaphylactic shock. Therefore, it is imperative that physicians administering allergenic extracts understand and be prepared for the treatment of severe reactions.
Other possible systemic reactions which may occur in varying degrees of severity are laryngeal edema, fainting, pallor, bradycardia, hypotension, angioedema, cough, wheezing, conjunctivitis, rhinitis, and urticaria. Adverse reaction frequency data for allergenic extract administration for testing and treatment show that risk is low. 1, 28 If a systemic or anaphylactic reaction does occur, apply a tourniquet above the site of injection and inject 1:1000 epinephrine-hydrochloride intramuscularly or subcutaneously into the opposite arm.
Loosen the tourniquet at least every 10 minutes. Do not obstruct arterial blood flow with the tourniquet. EPINEPHRINE DOSAGE: ADULT DOSAGE: 0.3 to 0.5 mL should be injected.
Repeat in 5 to 10 minutes if necessary. PEDIATRIC DOSAGE: The usual initial dose is 0.01 mg (mL) per kg body weight or 0.3 mg (mL) per square meter of body surface area. Suggested dosage for infants to 2 years of age is 0.05 to 0.1 mL; for children 2 to 6 years, 0.15 mL; and children 6 to 12 years, 0.2 mL.
Single pediatric doses should not exceed 0.3 mg (mL). Doses may be repeated as frequently as every 20 minutes, depending on the severity of the condition and the response of the patient. After administration of epinephrine, profound shock or vasomotor collapse should be treated with intravenous fluids, and possibly vasoactive drugs.
Airway patency should be insured. Oxygen should be given by mask. Intravenous antihistamine, theophylline and/or corticosteroids may be used if necessary after adequate epinephrine and circulatory support has been given.
Emergency resuscitation measures and personnel trained in their use should be available immediately in the event of a serious systemic or anaphylactic reaction not responsive to the above measures [ Ref. J. Allergy and Clinical Immunology , 77(2): p.
271-273, 1986]. Rarely are all of the above measures necessary; the tourniquet and epinephrine usually produce prompt responses. However, the physician should be prepared in advance for all contingencies.
Promptness in beginning emergency treatment measures is of utmost importance. Severe systemic reactions mandate a decrease of at least 50% in the next dose, followed by cautious increases. Repeated systemic reactions, even of a mild nature, are sufficient reason for the cessation of further attempts to increase the reaction-causing dose.
3. Adverse Event Reporting Report all adverse events to Jubilant HollisterStier LLC Customer Technical Services Department at 1 (800) 992-1120. A voluntary adverse event reporting system for health professionals is available through the FDA MEDWATCH program.
Preprinted forms (FDA Form 3500) a… [Excerpted — this section continues on DailyMed.]
🔄 Drug Interactions ▾
8. Drug Interactions Patients on non-selective beta blockers may be more reactive to allergens given for diagnosis or treatment, and may be unresponsive to the usual doses of epinephrine used to treat allergic reactions. 19 Certain medications may lessen the skin test wheal and erythema responses elicited by allergens and histamine for varying time periods.
Conventional antihistamines should be discontinued at least 5 days before skin testing. Long acting antihistamines should be discontinued for at least 3 weeks prior to skin testing. 2 Topical steroids should be discontinued at the skin test site for at least 2-3 weeks before skin testing.
2, 3 Tricyclic antidepressants such as Doxepin should be withheld for at least 7 days before skin testing. 31 Topical local anesthetics may suppress the flare responses and should be avoided in skin test sites. 4
🤰 Pregnancy ▾
4. Pregnancy 30 Pregnancy Category C. Allergenic Extracts.
Animal reproduction studies have not been conducted with allergenic extracts. It is also not known whether allergenic extracts can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Allergenic extracts should be given to a pregnant woman only if clearly needed.
For women who have been getting maintenance doses of allergen without side effect, the occurrence of pregnancy is not an indication to stop immunotherapy.
🧒 Pediatric Use ▾
6. Pediatric Use Since dosage for the pediatric population is the same as for adults 26, 27 , the larger volumes of solution may produce excessive discomfort. Therefore, in order to achieve the total dose required, the volume of the dose may need to be divided into more than one injection per visit.
4. Pediatric Use The dose for the pediatric population is the same as for adults. (See PRECAUTIONS .)
🧓 Geriatric Use ▾
7. Geriatric Use The reactions from immunotherapy can be expected to be the same in elderly patients as in younger ones. Elderly patients may be more likely to be on medication that could block the effect of epinephrine which could be used to treat serious reactions, or they could be more sensitive to the cardiovascular side effect of epinephrine because of pre-existing cardiovascular disease. 29
5. Geriatric Use The dose for elderly patients is the same as for adult patients under 65. 29
🆘 Overdosage ▾
OVERDOSAGE: See ADVERSE REACTIONS Section.
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY: 26 The mechanisms by which hyposensitization is achieved are not completely understood. It has been shown that repeated injections of appropriate allergenic extracts will ameliorate the intensity of allergic symptoms upon contact with the allergen. 6, 7, 8, 9 Clinical studies which address the efficacy of immunotherapy are available.
The allergens which have been studied are cat, mite, and some pollen extracts. 10, 11, 12, 13, 14, 15 IgE antibodies bound to receptors on mast cell membranes are required for the allergic reaction, and their level is probably related to serum IgE concentrations. Immunotherapy has been associated with decreased levels of IgE, and also with increases in allergen specific IgG "blocking" antibody.
The histamine release response of circulating basophils to a specific allergen is reduced in some patients by immunotherapy, but the mechanism of this change is not yet clear. The relationships among changes in blocking antibody, reaginic antibody, and mediator-releasing cells, and successful immunotherapy need study and clarification. Mites belonging to the genus Dermatophagoides are found in approximately 80% of house dust samples throughout the world.
22, 23 D. farinae is common in much of the United States, 24 although D. pteronyssinus is predominant in certain coastal regions, and both species are commonly found in homes. 25 Persons suspected of having allergy to house dust should be tested for sensitivity to each mite.
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED: Standardized allergenic extracts are supplied for diagnostic and therapeutic use: Diagnostics: Extracts: D. pteronyssinus and D. farinae Scratch, prick or puncture tests, 30,000 AU/mL [50% glycerin (v/v)] in 5 mL dropper vial. Intradermal Tests [Aqueous] of 30 AU/mL in 5 mL vial, and 300 AU/mL in 5 mL vial. Bulk Therapeutics [50% glycerin (v/v)] in multiple dose vials: Extracts: D. pteronyssinus and D. farinae 10 mL vial, 30,000 AU/mL or 10,000 AU/mL 30 mL vial, 30,000 AU/mL or 10,000 AU/mL 50 mL vial, 10,000 AU/mL A mixture of the two mite species, in equal parts, resulting in D. pteronyssinus at 15,000 AU/mL and D. farinae at 15,000 AU/mL is available for therapeutic use in 10 mL and 30 mL vials.
A mixture of the two species is also available at 5,000 AU/mL each species in 10 mL, 30 mL and 50 mL.
📦 Storage and Handling ▾
STORAGE: The expiration date of the mite extract in 50% glycerin is listed on the container label. The extract should be stored at 2° - 8°C and kept in this temperature range during office use. Dilutions containing less than 50% glycerin are less stable, and if loss of potency is suspected, should be checked by skin testing with equal units of a freshly prepared dilution on known mite allergic individuals.
The expiration date of the intradermal tests is listed on container labels. Store at 2° - 8°C.
📋 Description ▾
DESCRIPTION: Mite extract is a sterile solution containing the extractables of Dermatophagoides farinae or Dermatophagoides pteronyssinus , 0.5% sodium chloride, 0.275% sodium bicarbonate, and 50% glycerin by volume as a preservative. Source material for the extract is the whole bodies of the mites. The mites are grown on a medium of brine shrimp eggs and wheat germ, and are handled and cleaned in a manner that the maximum carryover of the medium components is less than 1%.
The medium contains no material of human origin. Sterile, diluted mite extracts available for intradermal testing contain 0.9% sodium chloride, not more than 0.5% glycerin by volume, 0.03% albumin (human), not more than 0.003% sodium bicarbonate, and 0.4% phenol as a preservative. Skin test trials were conducted to evaluate the skin reactivity of medium components mixed in the approximate proportion used for mite growth.
Twenty-three individuals who were puncture test reactive (∑E≥40mm) to either D. farinae or D. pteronyssinus were tested with an extract of medium components at an estimated 1% carryover level. None of these patients had a ∑E response more than 3mm larger than the negative control by puncture test with the concentrate of the medium components extract. One of the 23 patients had a reaction with ∑E≥20mm when tested intradermally with a 1:100 (v/v) dilution of the concentrate of the medium components extracts.
Standardized D. farinae and D. pteronyssinus extract concentrates (stock concentrates) containing 30,000 Allergy Units/mL (AU/mL) are supplied in dropper vials for scratch, prick or puncture tests. Stock concentrates are also available in multiple-dose vials containing 10,000 AU/mL and 30,000 AU/mL to be diluted for intradermal testing and immunotherapy. Standardized D. farinae and D. pteronyssinus extract dilutions (at 30 AU/mL and 300 AU/mL) are supplied for intradermal diagnostic tests described in Section DOSAGE AND ADMINISTRATION , Diagnosis, Part 2.a.
Product Concentration: 1. Allergy Units (AU/mL). The potency of extracts labeled in Allergy Units (AU/mL) is determined by in vitro comparison to a reference standard established by the Center for Biologics Evaluation and Research (CBER) of the Food and Drug Administration.
2. Bioequivalent Allergy Units (BAU/mL). Other standardized allergenic extracts are labeled in Bioequivalent Allergy Units/mL (BAU/mL) based on their comparison (by in vitro assay or major allergen content) to CBER, FDA Reference Preparations.
The FDA reference extracts have been assigned Bioequivalent Allergy Units based on the CBER ID 50 EAL method. 5 Briefly, highly sensitive patients are skin tested to the reference preparation using an intradermal technique employing 3-fold extract dilutions. Depending on the dilution which elicits a summation of erythema diameter of 50, Bioequivalent Allergy Units are assigned as follows: BAU/mL D 50 100,000 13-15 10,000 10.9-12.9 1,000 8.8-10.8 100 6.7-8.7 3.
Concentrate Concentrate label terminology applies to allergenic extract mixtures where the individual allergens being combined vary in strength or the designation of strength. e.g. Concentrate 50% Short Ragweed 1:20 w/v 25% Std Cat Hair 10,000 BAU/mL 25% Std Mite D. farinae 10,000 AU/mL Should the physician choose to calculate the actual strength of each component in the "Concentrate" mixture, the following formulation may be used: Actual Allergen Strength In concentrate Mixture = Allergen Manufacturing Strength X % allergen in Formulation (by volume or parts)
💬 Information for Patients ▾
2. Information for Patients Patients should be instructed in the recognition of adverse reactions to immunotherapy, and in particular, to the symptoms of shock. Patients should be made to understand the importance of a 30 minute observation period, and be warned to return to the office promptly if symptoms occur after leaving.
⚠️ Precautions ▾
PRECAUTIONS: 1. General The presence of asthmatic signs and symptoms appear to be an indicator for severe reactions following allergy injections. 1, 32, 33, 34, 35 An assessment of airway obstruction either by measurement of peak flow or an alternate procedure may provide a useful indicator as to the advisability of administering an allergy injection.
Concentrated extracts must be diluted prior to use; See DOSAGE AND ADMINISTRATION Section for detailed instructions on the dilution of standardized glycerinated allergenic extracts. Any evidence of local or generalized reaction requires a reduction in dosage during the initial stages of immunotherapy, as well as during maintenance therapy. Allergenic extracts diluted with Albumin Saline with Phenol (0.4%) may be more potent than extracts diluted with diluents which do not contain stabilizers.
When switching from non-stabilized to stabilized diluent, consider weaker initial dilutions for both intradermal testing and immunotherapy. Sterile solutions, vials, syringes, etc. should be used and aseptic precautions observed in making dilutions. To avoid cross-contamination, do not use the same needle to withdraw materials from vials of more than one extract, or extract followed by diluent.
A sterile tuberculin syringe graduated in 0.01 mL units should be used to measure each dose from the appropriate dilution. Aseptic techniques should always be employed when injections of allergenic extracts are being administered. A separate sterile syringe should be used for each patient to prevent transmission of homologous serum hepatitis and other infectious agents from one person to another.
Patient reactions to previous injections should be reviewed before each new injection. A conservative dosage schedule should be followed by the physician until a pattern of local responses is established which can be used to monitor increases in dosage. Rarely, a patient is encountered who develops systemic reactions to minute doses of allergen and does not demonstrate increasing tolerance to injections after several months of treatment.
If systemic reactions or excessive local responses occur persistently at very small doses, efforts at immunotherapy should be stopped. PATIENTS SHOULD BE OBSERVED IN THE OFFICE FOR 30 MINUTES AFTER EACH TREATMENT INJECTION. Most severe reactions will occur within this time period, and rapid treatment measures should be instituted.
See ADVERSE REACTIONS Section for such treatment measures. 2. Information for Patients Patients should be instructed in the recognition of adverse reactions to immunotherapy, and in particular, to the symptoms of shock.
Patients should be made to understand the importance of a 30 minute observation period, and be warned to return to the office promptly if symptoms occur after leaving. 3. Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term studies in animals have not been conducted with allergenic extracts to determine their potential for carcinogenicity, mutagenicity or impairment of fertility.
4. Pregnancy 30 Pregnancy Category C. Allergenic Extracts.
Animal reproduction studies have not been conducted with allergenic extracts. It is also not known whether allergenic extracts can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Allergenic extracts should be given to a pregnant woman only if clearly needed.
For women who have been getting maintenance doses of allergen without side effect, the occurrence of pregnancy is not an indication to stop immunotherapy. 5. Nursing Mothers There are no current studies on secretion of the allergenic extract components in human milk, or of their effect on the nursing infant.
Because many drugs are excreted in human milk, caution should be exercised when allergenic extracts are administered to a nursing woman. 6. Pediatric Use Since dosage for the pediatric population is the same as for adults 26, 27 , the larger volumes of solution may produce excessive discom… [Excerpted — this section continues on DailyMed.]
🍼 Nursing Mothers ▾
5. Nursing Mothers There are no current studies on secretion of the allergenic extract components in human milk, or of their effect on the nursing infant. Because many drugs are excreted in human milk, caution should be exercised when allergenic extracts are administered to a nursing woman.
📄 Carcinogenesis, Mutagenesis, Impairment of Fertility ▾
3. Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term studies in animals have not been conducted with allergenic extracts to determine their potential for carcinogenicity, mutagenicity or impairment of fertility.
📚 References ▾
REFERENCES: 1. Lockey, Richard F., Linda M. Benedict, Paul C.
Turkeltaub, Samuel C. Bukantz. Fatalities from immunotherapy (IT) and skin testing (ST).
J. Allergy Clin. Immunol., 79 (4): 660-677, 1987.
2. Pipkorn, Ulf. Pharmacological influence of anti-allergic medication on In Vivo allergen testing.
Allergy. 43: 81-86, 1988. 3.
Andersson, M.and U. Pipkorn. Inhibition of the dermal immediate allergic reaction through prolonged treatment with topical glucocorticosteroids.
J. Allergy Clin. Immunol.
79 (2): 345-349, February 1987. 4. Pipkorn, Ulf, and M.
Andersson. Topical dermal anesthesia inhibits the flare but not the wheal response to allergen and histamine in the skin prick test. Clinical Allergy.
17: 307-311, 1987. 5. Turkeltaub, Paul C., MD, and Suresh C.
Rastogi, PhD. Quantitative intradermal test procedure for evaluation of subject sensitivity to standardized allergenic extracts and for assignment of allergy units to reference preparations using the ID 50 EAL method, Allergenics Products Testing Laboratory, Center for Biologics Evaluation and Research (CBER), FDA. Revised: November 1994.
6. Lowell, F.C., W. Franklin.
A "double-blind" study of treatment with aqueous allergenic extracts in cases of allergic rhinitis. J. Allergy, 34 (2): 165-182, 1983.
7. Lowell, F.C., W. Franklin.
A double-blind study of the effectiveness and specificity of injection therapy in ragweed hay fever. N. Eng.
J. Med., 273 (13): 675-679, 1965. 8.
Zavazal, V., A. Stajner. Immunologic changes during specific treatment of the atopic state.
II. Acta. Allergol., 25 (1): 11-17, 1970.
9. Reisman, R.E., J.I. Wypych, E.E.
Arbesman. Relationship of immunotherapy, seasonal pollen exposure and clinical response to serum concentrations of total IgE and ragweed-specific IgE. Int.
Arch. Allergy Appl. Immunol., 48 (6): 721-730, 1975.
10. Taylor, W.W., J.L. Ohman, F.C.
Lowell. Immunotherapy in cat-induced asthma; double-blind trial with evaluation of bronchial responses to cat allergen and histamine. J.
Allergy Clin. Immunol., 61 (5): 283-287, 1978. 11.
Smith. A.P. Hyposensitization with Dermatophagoides pteronyssinus antigen: Trial in asthma induced by house dust.
Br. Med. J., 4: 204-206, 1971.
12. Chapman, M.D., T.A.E. Platts-Mills, M.
Gabriel, H.K. Ng, W.G.L. Allen, L.E.
Hill, A.J. Nunn. Antibody response following prolonged hyposensitization with Dermatophagoides pteronyssinus extract.
Int. Arch. Allergy Appl.
Immunol., 61: 431-440, 1980. 13. Norman, P.S.
Postgraduate course presentation. An overview of immunotherapy, implications for the future. J.
Allergy Clin. Immunol., 65 (2): 87-96, 1980. 14.
Norman, P.S., W.L. Winkenwerder. Maintenance immunotherapy in ragweed hay fever.
J. Allergy, 74: 273-282, 1971. 15.
Norman, P.S., W.L. Winkenwerder, L.M. Lichtenstein.
Immunotherapy of hay fever with ragweed antigen E; comparisons with whole pollen extract and placebos. J. Allergy, 42: 93-108, 1968.
16. Sheldon, J.M., R.G. Lovell, K.P.
Matthews. A Manual of Clinical Allergy. Second Edition.
W.B. Saunders, Philadelphia, 1967, pp. 107-112.
17. Sherman, W.B. Hypersensitivity Mechanism and Management.
W.B. Sanders, Philadelphia, 1968, pp. 169-172.
18. Swineford, O. Asthma and Hay Fever.
Charles C. Thomas, Springfield, IL, 1971, pp. 148-155.
19. Jacobs, R.L., G.W. Rake, Jr., et al.
Potentiated anaphylaxis in patients with drug-induced beta-adrenergic blockade. J. Allergy Clin.
Immunol., 68 (2): 125-127, August 1981. 20. Pauli, G., J.C.
Bessot, R. Thierry, and A. Lamensons.
Correlation between skin tests, inhalation tests and specific IgE in a study of 120 subjects to house dust and Dermatophagoides pteronyssinus. Clin. Allergy, 7:337, 1977.
21. Murray, A.B., A.C. Ferguson and B.J.
Morrison. Diagnosis of house dust mite allergy in asthmatic children: what constitutes positive history? J.
Allergy Clin. Immunol. 71:21, 1983.
22. Wharton, G.W. House Dust Mites.
J. Med. Entomol.
12:577, 1976. 23. Voorhorst, R., F.Th.M.
Spieksma and H. Varekamp. House Dust Atopy and the House… [Excerpted — this section continues on DailyMed.]
📄 Package Label / Principal Display Panel ▾
Example Vial Label
About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |